KETABON

Ketabon is a joint venture between HMNC Brain Health and Develco Pharma. The company develops an oral prolonged-release formulation of ketamine for Treatment-Resistant Depression (TRD) with minimal dissociative side effects. This prolonged-release formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects due to its unique pharmacokinetic profile compared to the currently applied intravenous and intranasal ketamine therapies. TRD patients with insufficient response to standard antidepressants represent 30% of an overall estimated number of 320 million patients worldwide suffering from major depressive disorder. In this group, prolonged-release ketamine has shown high response rates. Clinical development of oral prolonged-release ketamine could also potentially be expanded into other indications... Ketabon aims to unlock ketamine's full antidepressant potential while at the same time substantially limiting its side effects...

Also known as: Ketabon GmbH

Registration numbers: HRB 237179 (W)

VAT numbers: DE316656328

Primary location: München Czech Republic